Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 51

1.

Interactions between tamoxifen and antidepressants via cytochrome P450 2D6.

Desmarais JE, Looper KJ.

J Clin Psychiatry. 2009 Dec;70(12):1688-97. doi: 10.4088/JCP.08r04856blu. Review.

PMID:
20141708
2.

Addressing intimacy and partner communication after breast cancer: a randomized controlled group intervention.

Rowland JH, Meyerowitz BE, Crespi CM, Leedham B, Desmond K, Belin TR, Ganz PA.

Breast Cancer Res Treat. 2009 Nov;118(1):99-111. doi: 10.1007/s10549-009-0398-x. Epub 2009 Apr 24.

3.

Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial.

Kenemans P, Bundred NJ, Foidart JM, Kubista E, von Schoultz B, Sismondi P, Vassilopoulou-Sellin R, Yip CH, Egberts J, Mol-Arts M, Mulder R, van Os S, Beckmann MW; LIBERATE Study Group.

Lancet Oncol. 2009 Feb;10(2):135-46. doi: 10.1016/S1470-2045(08)70341-3. Epub 2009 Jan 23.

PMID:
19167925
4.

Testosterone for low libido in postmenopausal women not taking estrogen.

Davis SR, Moreau M, Kroll R, Bouchard C, Panay N, Gass M, Braunstein GD, Hirschberg AL, Rodenberg C, Pack S, Koch H, Moufarege A, Studd J; APHRODITE Study Team.

N Engl J Med. 2008 Nov 6;359(19):2005-17. doi: 10.1056/NEJMoa0707302.

5.

The effects of tibolone in older postmenopausal women.

Cummings SR, Ettinger B, Delmas PD, Kenemans P, Stathopoulos V, Verweij P, Mol-Arts M, Kloosterboer L, Mosca L, Christiansen C, Bilezikian J, Kerzberg EM, Johnson S, Zanchetta J, Grobbee DE, Seifert W, Eastell R; LIFT Trial Investigators.

N Engl J Med. 2008 Aug 14;359(7):697-708. doi: 10.1056/NEJMoa0800743.

6.

Reproductive steroid hormones and recurrence-free survival in women with a history of breast cancer.

Rock CL, Flatt SW, Laughlin GA, Gold EB, Thomson CA, Natarajan L, Jones LA, Caan BJ, Stefanick ML, Hajek RA, Al-Delaimy WK, Stanczyk FZ, Pierce JP; Women's Healthy Eating and Living Study Group.

Cancer Epidemiol Biomarkers Prev. 2008 Mar;17(3):614-20. doi: 10.1158/1055-9965.EPI-07-0761. Epub 2008 Mar 6.

7.

A case series of androgen use in breast cancer survivors with sexual dysfunction.

Krychman ML, Stelling CJ, Carter J, Hudis CA.

J Sex Med. 2007 Nov;4(6):1769-74. Epub 2007 Jul 31.

PMID:
17666036
8.

Symptom management after breast cancer treatment: is it influenced by patient characteristics?

Yoon J, Malin JL, Tisnado DM, Tao ML, Adams JL, Timmer MJ, Ganz PA, Kahn KL.

Breast Cancer Res Treat. 2008 Mar;108(1):69-77. Epub 2007 Jul 19.

PMID:
17638071
9.

Randomized controlled trial to evaluate transdermal testosterone in female cancer survivors with decreased libido; North Central Cancer Treatment Group protocol N02C3.

Barton DL, Wender DB, Sloan JA, Dalton RJ, Balcueva EP, Atherton PJ, Bernath AM Jr, DeKrey WL, Larson T, Bearden JD 3rd, Carpenter PC, Loprinzi CL.

J Natl Cancer Inst. 2007 May 2;99(9):672-9.

10.

An open-label, fixed-dose study of bupropion effect on sexual function scores in women treated for breast cancer.

Mathias C, Cardeal Mendes CM, Pondé de Sena E, Dias de Moraes E, Bastos C, Braghiroli MI, Nuñez G, Athanazio R, Alban L, Moore HC, del Giglio A.

Ann Oncol. 2006 Dec;17(12):1792-6. Epub 2006 Sep 15.

11.

Quality of life of postmenopausal women in the ATAC ("Arimidex", tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for early breast cancer.

Cella D, Fallowfield L, Barker P, Cuzick J, Locker G, Howell A; ATAC Trialistsa9 Group.

Breast Cancer Res Treat. 2006 Dec;100(3):273-84. Epub 2006 Jun 21.

PMID:
16944295
12.

Sexual problems in younger women after breast cancer surgery.

Burwell SR, Case LD, Kaelin C, Avis NE.

J Clin Oncol. 2006 Jun 20;24(18):2815-21.

13.

Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.

Land SR, Wickerham DL, Costantino JP, Ritter MW, Vogel VG, Lee M, Pajon ER, Wade JL 3rd, Dakhil S, Lockhart JB Jr, Wolmark N, Ganz PA.

JAMA. 2006 Jun 21;295(23):2742-51. Epub 2006 Jun 5. Erratum in: JAMA. 2007 Sep 5;298(9):973.

PMID:
16754728
14.

Phase III comparison of depomedroxyprogesterone acetate to venlafaxine for managing hot flashes: North Central Cancer Treatment Group Trial N99C7.

Loprinzi CL, Levitt R, Barton D, Sloan JA, Dakhil SR, Nikcevich DA, Bearden JD 3rd, Mailliard JA, Tschetter LK, Fitch TR, Kugler JW.

J Clin Oncol. 2006 Mar 20;24(9):1409-14. Epub 2006 Feb 27.

15.
16.

Caution: Vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors.

Kendall A, Dowsett M, Folkerd E, Smith I.

Ann Oncol. 2006 Apr;17(4):584-7. Epub 2006 Jan 27.

17.

Androgen therapy in women.

Arlt W.

Eur J Endocrinol. 2006 Jan;154(1):1-11. Review.

18.

Study of sexual functioning determinants in breast cancer survivors.

Speer JJ, Hillenberg B, Sugrue DP, Blacker C, Kresge CL, Decker VB, Zakalik D, Decker DA.

Breast J. 2005 Nov-Dec;11(6):440-7.

PMID:
16297089
19.

Safety and efficacy of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial.

Braunstein GD, Sundwall DA, Katz M, Shifren JL, Buster JE, Simon JA, Bachman G, Aguirre OA, Lucas JD, Rodenberg C, Buch A, Watts NB.

Arch Intern Med. 2005 Jul 25;165(14):1582-9.

PMID:
16043675
20.

Testosterone patch for low sexual desire in surgically menopausal women: a randomized trial.

Buster JE, Kingsberg SA, Aguirre O, Brown C, Breaux JG, Buch A, Rodenberg CA, Wekselman K, Casson P.

Obstet Gynecol. 2005 May;105(5 Pt 1):944-52.

PMID:
15863529
Items per page

Supplemental Content

Write to the Help Desk